Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy (IgAN).
Official title: A Phase 3b, Open-label, Single-arm, Patient Experience Study of Povetacicept Injection (Via Autoinjector) as Compared to Sibeprenlimab Injection (Via Prefilled Syringe) in Adults With Immunoglobulin A Nephropathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-10-23
Completion Date
2028-03-02
Last Updated
2026-10-22
Healthy Volunteers
No
Conditions
Interventions
Povetacicept
Subcutaneous injection administration.
Sibeprenlimab
Subcutaneous injection administration.